Gliomas: Signaling Pathways, Molecular Mechanisms and Novel Therapies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1450
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue delves into the rapidly evolving field of glioma's molecular intricacies, with a specific focus on the role of signal pathways and their implications for novel therapeutic strategies. Gliomas, originating from the transformation of glial cells, are marked by a complex array of genetic, epigenetic, and signaling alterations. These include mutations in pivotal genes such as IDH1/2, TP53, and ATRX in lower-grade gliomas; PTEN, EGFR, and PDGFRA in primary glioblastomas; and DNA methylation and histone modifications. Crucially, this Special Issue highlights how disruptions in signal transduction pathways, such as the RTK/RAS/PI(3)K pathway, play a central role in glioma pathogenesis and offer potential targets for therapy.
A key focus of this Special Issue is on the innovative treatment strategies emerging in response to these challenges, particularly those targeting aberrant signaling in gliomas. Advances in immunotherapy, such as checkpoint inhibitors and CAR T-cell therapy, are being adapted to target the immunosuppressive tumor microenvironment and navigate the blood–brain barrier (BBB). Additionally, we explore gene therapy techniques using viral vectors for direct tumor targeting and the application of nanomedicine for enhanced drug delivery, both of which are critical in manipulating signaling pathways within the tumor.
The objective is to present a comprehensive overview of the current state of glioma treatment research, with a special emphasis on signal pathways. This includes illustrating the promising therapeutic avenues that are arising and acknowledging the considerable challenges that remain. We aim to foster a deeper understanding of these advancements and hurdles among researchers, clinicians, and stakeholders, with the ultimate goal of driving forward innovations that promise improved outcomes for glioma patients.
Dr. Hung-Pei Tsai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- molecular pathology
- blood–brain barrier
- immunotherapy
- microenvironment
- nanomedicine
